Few investigators have examined other oncodriver expression in DCIS of mutation carriers, and thus our study evaluating HER1, HER3, and C-MET adds to the current body of literature regarding immunophenotypes of hereditary breast cancer. This evidence concerns the gene MET and breast carcinoma.